CHIROGATE INTERNATIONAL INC.

Founded in 1999 and based in Taiwan, CHIROGATE INTERNATIONAL INC. is a manufacturer, trading company, and service provider with a strong track record in regulated markets. Since achieving cGMP compliance in 2003, the company has filed its first US DMF, passed multiple US FDA inspections (2006 and 2010), and expanded to six dedicated production lines; it holds a substantial patent portfolio spanning the US and Europe (including patents for latanoprost-related processes) and counts several of the world's top ten generics companies among its customers. Chirogate sells across North America, Central/South America, Western and Eastern Europe, Australasia, Asia, and the Middle East, valuing international certifications, an experienced R&D staff, production capacity, and its long-standing industry reputation.